A case of esophageal adenocarcinoma on long-term rapamycin monotherapy

Area of Science:

• Oncology
• Transplantation Medicine
• Immunosuppression Therapy

Background:

• Cancer development is a significant risk in transplant recipients due to long-term immunosuppression.
• Mammalian target of rapamycin (mTOR) inhibitors are used in transplantation and possess potential anticancer properties.
• Managing secondary malignancies in transplant patients on immunosuppressive drugs presents unique challenges.

Observation:

• A 78-year-old kidney transplant recipient developed Kaposi's Sarcoma six months post-transplant while on cyclosporine.
• The patient later developed esophageal adenocarcinoma stage IIA in 2007.
• The patient was switched to sirolimus monotherapy in 2001, leading to complete recovery from Kaposi's Sarcoma within two years.

Findings:

• Sirolimus monotherapy demonstrated efficacy in treating multifocal cutaneous Kaposi's Sarcoma in a transplant recipient.
• The patient experienced no recurrence of Kaposi's Sarcoma or esophageal adenocarcinoma while maintained on sirolimus.
• The case suggests a potential role for sirolimus in managing specific cancers in immunosuppressed patients.

Implications:

• This case underscores the complex relationship between immunosuppression, cancer, and therapeutic interventions in transplant patients.
• Further research into the anticancer effects of mTOR inhibitors like sirolimus in transplant recipients is warranted.
• Sirolimus monotherapy may offer a viable treatment option for certain malignancies in the context of post-transplant care.